GSK PLC GLAXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline — Update
-
GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline
-
GSK Gets U.S. Approval for Jideytro for Certain Lung Cancers
-
GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment
-
GSK Stops Development of Drug Candidate for Chronic Cough
-
Sino Biopharm Strikes Drug Licensing Deal With AstraZeneca, Deepens Partnership With GSK — Update
-
GSK, Spero Therapeutics Gain U.S. Approval for Utebzi
-
Nuvalent Shares Leap Premarket on Takeover by GSK
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 4.01B
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 10.64
- Price/Sales
- 2.33
- Dividend Yield (Trailing)
- 3.61%
- Dividend Yield (Forward)
- 3.63%
- Total Yield
- 5.24%
Company Profile
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 66,841
- Website
- https://www.gsk.com
Competitors
Valuation
|
Metric
|
GLAXF
|
AZN
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.64 | 15.86 | 42.36 |
Price/Book Value | 4.34 | 4.68 | 8.00 |
Price/Sales | 2.33 | 3.92 | 5.07 |
Price/Cash Flow | 9.94 | 15.50 | 15.22 |
Price/Earnings
GLAXF
AZN
MRK
Financial Strength
|
Metric
|
GLAXF
|
AZN
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.52 | 0.66 | 0.71 |
Current Ratio | 0.82 | 0.89 | 1.32 |
Interest Coverage | 9.51 | 7.99 | 4.28 |
Quick Ratio
GLAXF
AZN
MRK
Profitability
|
Metric
|
GLAXF
|
AZN
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 11.66% | 9.00% | 6.27% |
Return on Equity (Normalized) | 42.98% | 21.69% | 16.68% |
Return on Invested Capital (Normalized) | 22.63% | 14.36% | 9.82% |
Return on Assets
GLAXF
AZN
MRK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|pX@sfw@ | LOCK|G& | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|@tRh#Bq | LOCK|dj& | $632B | |||
| AbbVie Inc
ABBV
| LOCK|sV@k?D | LOCK|## | $442B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|GP&F$jrv | LOCK|^$S | $350B | |||
| Merck & Co Inc
MRK
| LOCK|dzzv^P> | LOCK|RP% | $335B | |||
| Novartis AG ADR
NVS
| LOCK|B?bs$V^d | LOCK|%Z | $289B | |||
| AstraZeneca PLC
AZN
| LOCK|$?j!ztDZ | LOCK|?$ | $240B | |||
| Amgen Inc
AMGN
| LOCK|r@wv!?Ws | LOCK|w$& | $227B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|$$n<DC | LOCK|L^h | $201B | |||
| Gilead Sciences Inc
GILD
| LOCK|T<jH^V< | LOCK|C? | $172B |
United States